Monoclonal Antibodies (mAbs) Global Market Opportunities And Strategies To 2033

Apr 2024| TBR593F| TBRC (Publisher)

Sample Report

Report Highlights

Including: 1) By Source: Murine; Chimeric; Humanized; Human
2) By Application: Anti-Cancer; Immunological; Infectious Diseases; Hematological Disease
3) By End-Users: Hospitals; Specialty Centers
Covering: Johnson & Johnson Inc.; Merck & Co., Inc.; F. Hoffman-La Roche Ltd.; Bristol Myers Squibb; GlaxoSmithKline plc

Monoclonal Antibodies (mAbs) Global Market Opportunities And Strategies To 2033 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global monoclonal antibodies (mAbs) market as it emerges from the COVID-19 shut down.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 12 geographies.
Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
Create regional and country strategies based on local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market research findings.
Benchmark performance against key competitors.
Utilize the relationships between key data sets for superior strategizing.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis

Description:
Where is the largest and fastest-growing market for monoclonal antibodies (mAbs)? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The monoclonal antibodies (mAbs) market global report from The Business Research Company answers all these questions and many more.
The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market’s history and forecasts market growth by geography. It places the market within the context of the wider monoclonal antibodies (mAbs) market; and compares it with other markets.

The report covers the following chapters:

Introduction And Market Characteristics - Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by source, by application and by end-users market.
Key Trends - Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
Macro-Economic Scenario - The report provides an analysis of the impact of the COVID-19 pandemic, impact of the Russia-Ukraine war and impact of rising inflation on global and regional markets, providing strategic insights for businesses in the monoclonal antibodies (mAbs) market.
Global Market Size and Growth - Global historic (2018-2023) and forecast (2023-2028, 2033F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
Regional And Country Analysis - Historic (2018-2023) and forecast (2023-2028, 2033F) market values and growth and market share comparison by region and country.
Market Segmentation - Contains the market values (2018-2023) (2023-2028, 2033F) and analysis for each segment by source, by application and by end-users in the market. Historic (2018-2023) and forecast (2023-2028) and (2028-2033) market values and growth and market share comparison by region market.
Regional Market Size And Growth - Regional market size (2023), historic (2018-2023) and forecast (2023-2028, 2033F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
Competitive Landscape - Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
Key Mergers And Acquisitions - Information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions, which have shaped the market in recent years.
Market Opportunities And Strategies - Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
Conclusions And Recommendations- This section includes recommendations for monoclonal antibodies (mAbs) providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
Appendix - This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.

Report Synopsis

Report Metrics	Details
Base year considered	2023
Forecast period considered	2023-2028
Units considered	$ Million
Segments covered	By Source, By Application, By End-Users
Industry covered	Pharmaceuticals
Regions covered	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Countries covered	China, Australia, India, Indonesia, Japan, South Korea, USA, Brazil, France, Germany, UK, Russia
Companies studied	Bristol Myers Squibb; Johnson & Johnson Inc.; Merck & Co., Inc.; F. Hoffman-La Roche Ltd.; GlaxoSmithKline plc

Scope

Markets Covered:

By Source: Murine; Chimeric; Humanized; Human
By Application: Anti-Cancer; Immunological; Infectious Diseases; Hematological Disease; Other Applications
By End-Users: Hospitals; Specialty Centers; Other End-Users

Companies Mentioned: Johnson & Johnson Inc.; Merck & Co., Inc.; F. Hoffman-La Roche Ltd.; Bristol Myers Squibb; GlaxoSmithKline plc

Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; Brazil; France; Germany; UK; Russia

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time-series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; monoclonal antibodies (mAbs) indicators comparison.

Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Table 1 : Global Monoclonal Antibodies (mAbs) Market, Historic, 2018 – 2023, $ Million
Table 2 : Global Monoclonal Antibodies (mAbs) Market, Forecast, 2023 – 2028, 2033F, $ Million
Table 3 : Global Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Table 4 : Global Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Table 5 : Global Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Table 6 : Global Monoclonal Antibodies (mAbs) Market, By Region, Historic and Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Table 7 : Global Monoclonal Antibodies (mAbs) Market, By Country, Historic and Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Table 8 : Asia-Pacific GDP Per Capita, By Country, 2018-2023, $
Table 9 : Asia-Pacific Population, By Country, 2018-2028, Millions
Table 10 : Asia-Pacific Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Table 11 : Asia-Pacific Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Table 12 : Asia-Pacific Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Table 13 : China GDP Per Capita, 2018-2023, $
Table 14 : China Population, 2018-2028, Millions
Table 15 : China Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Table 16 : China Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Table 17 : China Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Table 18 : India Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Table 19 : India Monoclonal antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Table 20 : India Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Table 21 : Japan Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Table 22 : Japan Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Table 23 : Japan Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Table 24 : Australia Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Table 25 : Australia Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Table 26 : Australia Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Table 27 : Indonesia Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Table 28 : Indonesia Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Table 29 : Indonesia Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Table 30 : South Korea Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Table 31 : South Korea Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Table 32 : South Korea Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Table 33 : Western Europe GDP Per Capita, By Country, 2018-2023, $
Table 34 : Western Europe Population, By Country, 2018-2028, Millions
Table 35 : Western Europe Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Table 36 : Western Europe Monoclonal Antibodies (Mabs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Table 37 : Western Europe Monoclonal Antibodies (Mabs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Table 38 : UK Monoclonal Antibodies (Mabs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Table 39 : UK Monoclonal Antibodies (Mabs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Table 40 : UK Monoclonal Antibodies (Mabs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Table 41 : Germany Monoclonal Antibodies (Mabs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Table 42 : Germany Monoclonal Antibodies (Mabs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Table 43 : Germany Monoclonal Antibodies (Mabs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Table 44 : France Monoclonal Antibodies (Mabs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Table 45 : France Monoclonal Antibodies (Mabs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Table 46 : France Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Table 47 : Eastern Europe GDP Per Capita, By Country, 2018-2023, $
Table 48 : Eastern Europe Population, By Country, 2018-2028, Millions
Table 49 : Eastern Europe Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Table 50 : Eastern Europe Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Table 51 : Eastern Europe Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Table 52 : Russia Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Table 53 : Russia Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Table 54 : Russia Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Table 55 : North America GDP Per Capita, By Country, 2018-2023, $
Table 56 : North America Population, By Country, 2018-2028, Millions
Table 57 : North America Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Table 58 : North America Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Table 59 : North America Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Table 60 : USA GDP Per Capita, 2018-2023, $
Table 61 : USA Population, 2018-2028, Millions
Table 62 : USA Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Table 63 : USA Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Table 64 : USA Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Table 65 : South America GDP Per Capita, By Country, 2018-2023, $
Table 66 : South America Population, By Country, 2018-2028, Millions
Table 67 : South America Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Table 68 : South America Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Table 69 : South America Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Table 70 : Brazil Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Table 71 : Brazil Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Table 72 : Brazil Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Table 73 : Middle East GDP Per Capita, By Country, 2018-2023, $
Table 74 : Middle East Population, By Country, 2018-2028, Millions
Table 75 : Middle East Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Table 76 : Middle East Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Table 77 : Middle East Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Table 78 : Africa GDP Per Capita, By Country, 2018-2023, $
Table 79 : Africa Population, By Country, 2018-2028, Millions
Table 80 : Africa Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Table 81 : Africa Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Table 82 : Africa Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Table 83 : Global Monoclonal Antibodies (mAbs) Market, Key Competitor Estimated Market Shares, 2022, Percentage (%)
Table 84 : Johnson & Johnson – Financial Overview, 2018 – 2022, $ Billion
Table 85 : Merck & Co – Financial Overview, 2018 – 2022, $ Billion
Table 86 : F. Hoffmann-La Roche Ltd – Financial Overview, 2018 – 2022, $ Billion
Table 87 : Bristol-Myers Squibb – Financial Overview, 2018 – 2022, $ Billion
Table 88 : GlaxoSmithKline plc – Financial Overview, 2018 – 2022, $ Billion
Table 89 : Global Monoclonal Antibodies (MAbs) Market, Pipeline Analysis
Table 90 : Global Monoclonal Antibodies (mAbs) Market Size Gain ($ Million), 2023 – 2028, By Country
Table 91 : Global Monoclonal Antibodies (mAbs) Market Size Gain ($ Million), Segmentation By Source, 2023 – 2028
Table 92 : Global Monoclonal Antibodies (mAbs) Market Size Gain ($ Million), Segmentation By Application, 2023 – 2028
Table 93 : Global Monoclonal Antibodies (mAbs) Market Size Gain ($ Million), Segmentation By End-Users, 2023 – 2028
Table 94 : Monoclonal Antibodies (mAbs) Market Data Sources

Figure 1 : Global Monoclonal Antibodies (mAbs) Market Segmentation By Source
Figure 2 : Global Monoclonal Antibodies (mAbs) Market Segmentation By Application
Figure 3 : Global Monoclonal Antibodies (mAbs) Market Segmentation By End-Users
Figure 4 : Global Monoclonal Antibodies (mAbs) Market, Historic, 2018 – 2023, $ Million
Figure 5 : Global Monoclonal Antibodies (mAbs) Market, Forecast, 2023 – 2028, 2033F, $ Million
Figure 6 : Global Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Figure 7 : Global Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Figure 8 : Global Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Figure 9 : Global Monoclonal Antibodies (mAbs) Market, By Region, Historic and Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Figure 10 : Global Monoclonal Antibodies (mAbs) Market, By Country, Historic and Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Figure 11 : Asia-Pacific Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Figure 12 : Asia-Pacific Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Figure 13 : Asia-Pacific Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Figure 14 : China Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Figure 15 : China Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Figure 16 : China Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Figure 17 : India Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Figure 18 : India Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Figure 19 : India Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Figure 20 : Japan Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Figure 21 : Japan Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Figure 22 : Japan Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Figure 23 : Australia Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Figure 24 : Australia Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Figure 25 : Australia Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Figure 26 : Indonesia Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Figure 27 : Indonesia Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Figure 28 : Indonesia Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Figure 29 : South Korea Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Figure 30 : South Korea Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Figure 31 : South Korea Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Figure 32 : Western Europe Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Figure 33 : Western Europe Monoclonal Antibodies (Mabs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Figure 34 : Western Europe Monoclonal Antibodies (Mabs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Figure 35 : UK Monoclonal Antibodies (Mabs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Figure 36 : UK Monoclonal Antibodies (Mabs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Figure 37 : UK Monoclonal Antibodies (Mabs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Figure 38 : Germany Monoclonal Antibodies (Mabs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Figure 39 : Germany Monoclonal Antibodies (Mabs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Figure 40 : Germany Monoclonal Antibodies (Mabs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Figure 41 : France Monoclonal Antibodies (Mabs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Figure 42 : France Monoclonal Antibodies (Mabs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Figure 43 : France Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Figure 44 : Eastern Europe Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Figure 45 : Eastern Europe Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Figure 46 : Eastern Europe Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Figure 47 : Russia Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Figure 48 : Russia Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Figure 49 : Russia Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Figure 50 : North America Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Figure 51 : North America Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Figure 52 : North America Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Figure 53 : USA Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Figure 54 : USA Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Figure 55 : USA Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Figure 56 : South America Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Figure 57 : South America Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Figure 58 : South America Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Figure 59 : Brazil Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Figure 60 : Brazil Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Figure 61 : Brazil Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Figure 62 : Middle East Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Figure 63 : Middle East Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Figure 64 : Middle East Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Figure 65 : Africa Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Figure 66 : Africa Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Figure 67 : Africa Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 – 2023, 2028F, 2033F, $ Million
Figure 68 : Global Monoclonal Antibodies (mAbs), Key Competitor Estimated Market Shares, 2022, Percentage (%)
Figure 69 : Johnson & Johnson – Financial Overview, 2018 – 2022, $ Billion
Figure 70 : Merck & Co – Financial Overview, 2018 – 2022, $ Billion
Figure 71 : F. Hoffmann-La Roche Ltd – Financial Overview, 2018 – 2022, $ Billion
Figure 72 : Bristol-Myers Squibb – Financial Overview, 2018 – 2022, $ Billion
Figure 73 : GlaxoSmithKline plc – Financial Overview, 2018 – 2022, $ Billion
Figure 74 : Geographic Regions Covered

The Business Research Company is a market research and intelligence company which excels in company, market and consumer research. It has over 50 research professionals at its offices in India, the UK and the US as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.

Similar Reports from TBRC (Publisher)

Monoclonal Antibodies (MAbS) Global Market Report 2023

Published Date - Feb 2023
Report Code - TBR593E

Including: 1) By Source: Murine; Chimeric; Humanized; Human
2) By Application: Anti-Cancer; Immunological; Anti-Infective Monoclonal Antibodies (MAbs); Neuropharmacological; Cardiovascular And Cerebrovascular
3) By End Users: Hospitals; Private Clinics; Research Institute
Covering: Johnson & Johnson; Merck; AbbVie; Amgen; Glaxosmithkline plc

Monoclonal Antibodies (MAbS) Global Market Report 2023 from The Business Research Company provides strategists, marketers and senior management with ...

Monoclonal Antibodies (MAbS) Global Market Report 2022

Published Date - Mar 2022
Report Code - TBR593D

Including: 1) By Source: Murine; Chimeric; Humanized; Human
2) By Application: Anti-Cancer; Immunological; Anti-Infective Monoclonal Antibodies (MAbs); Neuropharmacological; Cardiovascular And Cerebrovascular; Others
3) By End Users: Hospitals; Private Clinics; Research Institute
Covering: Johnson & Johnson; Merck; AbbVie; Amgen; Glaxosmithkline plc.; Norvatis AG; Pfizer inc.; Thermofischer Scientific; Elililly and Company

Monoclonal Antibodies (MAbS) Global Market Report 2022 from ...

Monoclonal Antibodies (MAbS) Global Market Report 2021: COVID 19 Impact and Recovery to 2030

Published Date - Apr 2021
Report Code - TBR593C

Including: 1) By Source: Murine; Chimeric; Humanized; Human
2) By Application: Anti-Cancer; Immunological; Anti-Infective Monoclonal Antibodies (MAbs); Neuropharmacological; Cardiovascular And Cerebrovascular; Others
3) By End Users: Hospitals; Private Clinics; Research Institute
Covering: Johnson & Johnson; Merck; AbbVie; Amgen; Glaxosmithkline plc

Monoclonal Antibodies (MAbS) Global Market Report 2021: COVID 19 Impact and Recovery to 2030 from The Business ...

Monoclonal Antibodies (MAbS) Global Market Report 2020-30: Covid 19 Impact and Recovery

Published Date - Oct 2020
Report Code - TBR593B

Covering: Johnson & Johnson; Merck; AbbVie; Amgen; Glaxosmithkline plc

Monoclonal Antibodies (MAbS) Global Market Report 2020-30: Covid 19 Impact and Recovery from The Business Research Company provides strategists, marketers ...

Monoclonal Antibodies (MAbS) Global Market Report 2020

Published Date - Dec 2019
Report Code - TBR593A

Including: 1) By Source: Murine, Chimeric, Humanized, Human 2) By Application: Anti-Cancer, Immunological, Anti-Infective Monoclonal Antibodies (MAbs), Neuropharmacological, Cardiovascular And Cerebrovascular, Others 3) By End Users: Hospitals, Private Clinics, Research Institute
Covering: Johnson & Johnson, Merck, AbbVie, Amgen, Glaxosmithkline plc